Regional Sales Manager – Breast Surgery - Lonestar (Texas, Oklahoma, New Mexico, Utah, Arizona)

At Hologic, we’re an innovative medical technology company that enables healthier lives everywhere, every day. We are also a company that prospers and grows, which is why we’ve been able to expand our offerings to empower even more people and champion women’s health.

What powers our growth across Breast & Skeletal Health, Diagnostics, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven capacity of our products to detect, diagnose, and treat illnesses and other health conditions early and with confidence. Our performance creates high expectations, which we fulfill by continually challenging ourselves to improve health through better technology, education, and market access.

None of this would be possible without the talent and passion of our employees. Together, our expertise and dedication to developing and sharing more robust, science-based certainty drives our global presence and a promising pipeline that responds to the unmet health and wellness needs of women, families, and communities.

While we focus on women’s health and well-being, we are committed to having an even broader benefit in the world. Together, we advocate for better health and wellness through solutions that provide ever greater certainty and peace of mind.

What to Expect:

Drives Results and Sales and Regional Business Performance:

Develops and executes against strategic regional business plans to assure sustainable and profitable business results.
Is self-directed in working with their sales team to meet and exceed business objectives.
Assures their sales team solves the business need of customer not just the sales of the product.
Collaborates with other Hologic team members and other Hologic resources to achieve desired customer outcomes.
Displays Business Acumen and Organizational Astuteness:
Understands customer’s and company’s business and financial drivers to assist his sales team in developing business solutions.
Assures they and their sales team are current on the health care field, competitive products, legislation and relevant disease states.
Builds and leverages relationships at all levels and networks both internally and externally to achieve desired results.
Anticipates and navigates situational resistance within their region to new ideas or business development efforts to gain agreement/acceptance.

Influences, Negotiates and Communicates for Impact:

Is effective at asking relevant questions and listening to understand business issues and goals within their region and provide mutually beneficial business solutions.
Builds strong relationships with internal team members and external contacts based on trust and communication.
Develops, manages and negotiates in conjunction with National Accounts new and ongoing purchasing agreements with IDNs and GPOs in their region.
Determines what is relevant to different audiences and applies to deliver high impact presentations and make compelling cases.

Demonstrates Critical Thinking and Emotional Intelligence:

Embraces and encourages learning new skills, knowledge, and behaviors.
Works to become more self-aware and demonstrates self-regulation in making business and personnel decisions.
Displays ability to properly define business problems and /or opportunities and develop effective solutions based on information, facts and evidence.

Displays Accountability and Leads and Develops Others:

Creates and leads plans for change within their region.
Understands and focuses on driving sustainable results.
Demonstrates ability to attract and select strong performer with potential.
Provides insight, coaching and development to grow their direct reports to their full potential.
Holds self and their direct reports accountable to fulfill commitments and model all behaviors asked of others.

What We Expect:

Education:

Bachelor’s degree required in a scientific, biomedical, business or marketing discipline.

Experience:

3+ years track record of leading and managing high sales performance teams (Top 20% of year over year) has even higher weight.
Knowledge of the health care industry and experience selling to hospitals, cancer centers, and surgeons is important. Experience selling biomedical, medical devices or imaging is a plus

Additional Details:

Since this position requires extensive driving during the workday, a valid driving license and satisfactory driving record, as well as a serviceable vehicle available for work use is mandatory. The position requires traveling to regional accounts and medical conventions which may necessitate overnight stays.
This role is based on a base salary and commission plan combination. On target compensation range for a highly successful individual may earn up to $330,000 annually. Final compensation packages will ultimately depend on factors including relevant experience, skillset, knowledge, territory/ geography, education, business needs, market demand and performance versus quota.
The Regional Sales Manager is accountable for the assigned region and other territories as assigned by their manager.
The Regional Sales Manager’s impact will reach their sales team and other corporate resources to achieve desired customer outcomes and company and regional goals. They will coach and develop their direct reports to ensure bench strength and will groom high potentials for next Hologic career opportunities.
The Regional Sales Manager, in consultation with their direct manager, will be expected to properly define regional business problems and develop effective solutions based on information, facts and evidence with minimal support. Is self-directed in driving to meet and exceed business objectives, within bounds determined by their manager

Agency and Third Party Recruiter Notice:

Agencies that submit a resume to Hologic must have a current executed Hologic Agency Agreement executed by a member of the Human Resource Department. In addition, Agencies may only submit candidates to positions for which they have been invited to do so by a Hologic Recruiter. All resumes must be sent to the Hologic Recruiter under these terms, or they will not be considered.

Hologic’s employees are subject to third-party COVID-19 vaccination requirements, including from customers and governmental entities. Hologic is an equal opportunity employer and consistent with federal, state, and local requirements, will consider requests for reasonable accommodation based on disability or sincerely held religious beliefs where it is able to do so without undue hardship to the company.

Hologic, Inc. is proud to be an Equal Opportunity Employer inclusive of disability and veterans.

#LI-SL2

About the company

Hologic develops medical technology to improve health through early detection and treatment. It designs, manufactures, and sells devices and diagnostic tests for breast and skeletal health, general diagnostics, GYN surgery, and medical aesthetics, sold to hospitals, labs, and providers with related services. Products enable screening, imaging, and guiding treatment in clinical settings. Its goal is to improve health outcomes by providing accurate diagnostics and reliable tools to support healthcare providers worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Santa Clara, null

Founded

1985

Get referred to Hologic

See people who can refer or advise you

Simplify's Take

What believers are saying

Hologic became private on April 7, 2026, giving Blackstone and TPG restructuring freedom.
FDA approval on February 4, 2026 expanded Aptima HPV screening options across modalities.
Hologic’s July 14, 2026 CE-IVDR expansion opens self-collected HPV testing in Europe and Britain.

What critics are saying

FDA says biopsy-needle shortages from Hologic’s January 2026 recall last through March 2027.
Redact ransomware reporting on June 28, 2026 exposed Hologic’s healthcare cybersecurity weakness.
Blackstone and TPG’s April 2026 buyout increases leverage, forcing asset sales by 2027.

What makes Hologic unique

Women’s-health focus spans breast imaging, diagnostics, and gynecologic surgery.
June 10, 2026 UPC ruling validated Hologic’s Envision mammography patent against Siemens.
Aptima and Panther platforms create sticky consumables, instruments, and lab workflow lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Retirement Plan
Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Yahoo Finance

Oct 19th, 2026

Hologic to acquire Barcelona-based Reveal Genomics to expand breast cancer diagnostics

Hologic, a women's health company, has signed a definitive agreement to acquire Reveal Genomics, a Barcelona-based precision oncology company. Financial terms were not disclosed. Reveal Genomics develops genomic tests to personalise cancer treatment, including HER2DX, which helps optimise therapy for patients with HER2-positive breast cancer. The tests complement Hologic's Breast Cancer Index (BCI) test, which informs decisions on extended endocrine therapy in women with HR+ early-stage breast cancer. Vitor Rocha, chief executive officer of Diagnostic Solutions at Hologic, said the deal would help it "support even more women diagnosed with breast cancer." Patricia Villagrasa-Gonzalez, Reveal Genomics' chief executive officer and co-founder, said Hologic gives it the scale to reach more patients worldwide. Completion depends on Spanish regulatory approval and other customary closing conditions.

Hologic

Sep 4th, 2026

Hologic's Fluent(R) Pro system wins International Design Excellence Award for user-centric innovation in women's health.

Hologic's Fluent(R) Pro system wins International Design Excellence Award for user-centric innovation in women's health. September 4, 2026 Technology honored for design that helps simplify fluid management and visualization during hysteroscopic procedures MARLBOROUGH, Mass. - Hologic, a global leader in women's health, has been honored with an International Design Excellence Award (IDEA) for its Fluent Pro fluid management system, which supports visualization and fluid control during hysteroscopy. "This award reflects our team's dedication to thoughtful design, clinical partnership and continuous innovation," said Brandon Schnittker, CEO, GYN Surgical Solutions. "Our goal has always been to help serve more patients while continuing to meet the evolving needs of our customers. The Fluent Pro system is a strong example of how purposeful, user-centric design can make complex procedures feel simpler and more intuitive for the teams who rely on our technologies every day." Presented annually by the Industrial Designers Society of America (IDSA), one of the longest-standing and largest industrial design associations in existence, the International Design Excellence Awards recognize design excellence across industries and disciplines. This year the organization received more than 2,000 entries. The Fluent Pro system is designed to deliver seamless integration and an intuitive user experience that supports procedural performance, including during procedures that use the MyoSure(R) tissue removal system, a device that removes fibroids and polyps through hysteroscopy. The user interface provides setup, operation and troubleshooting help screens that are easily accessible throughout the procedure. The system also provides suction control to resect simple to complex types of pathology designed for improved MyoSure procedures. The Fluent Pro interface aims to support the broader operating room team, including physicians performing procedures and nursing staff coordinating setup and room flow. Its user-centric design reflects the realities of the clinical environment, helping physicians stay focused on patient care and procedural execution. The system is also designed to simplify workflows and help teams operate with greater consistency and confidence. More than 1,020 hospital systems across the United States use the Fluent Pro system, allowing clinical teams nationwide to benefit from this award-winning technology. About Hologic, Inc. Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube. Forward-Looking Statements This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. Hologic, Fluent and MyoSure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Notes and Disclaimers Important Safety Information The Fluent(R) Pro fluid management system is intended to provide liquid distension of the uterus during diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation liquid flowing into and out of the uterus while providing drive, control and suction for hysteroscopic morcellators, specifically for the MyoSure(R) tissue removal device. The Fluent Pro fluid management system may not be used to introduce fluids into the uterus when hysteroscopy is contraindicated. The system should not be used to remove pathologies from pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer. For detailed benefit and risk information, please consult the Instructions For Use. Media Contact: Bridget Perry Senior Director, Corporate Communications (+1) 508.263.8654 [email protected]

Welcome.AI

Aug 7th, 2026

AI Cytology Screening market growth and challenges through 2033.

AI Cytology Screening market growth and challenges through 2033. Significant growth is on the horizon for the AI in cytology screening device market, with projections indicating an increase to over USD 330 million by 2033 as healthcare systems seek efficient diagnostic solutions. Key facts. * AI in cytology market projected to grow from $122.6M in 2026 to $330.9M by 2033 (CAGR 15.2%). * North America leads with 39.9% market share; Asia Pacific fastest-growing region indicates shifts. * High implementation costs hinder adoption in smaller labs, revealing vulnerability in market access. * Hologic's FDA approval for Genius system enhances competitive positioning in cervical cancer diagnostics. * Cloud-based solutions expected to grow rapidly, indicating strategic shift towards scalable AI technologies. Summary. The AI in cytology screening device market is poised for significant growth, projected to expand from USD 122.6 million in 2026 to USD 330.9 million by 2033, reflecting a compound annual growth rate (CAGR) of 15.2%. This growth is primarily driven by the increasing demand for improved diagnostic accuracy in the face of a global shortage of skilled cytologists. As healthcare providers seek to enhance laboratory efficiency and reduce the manual workload, the integration of artificial intelligence into cytology screening is becoming a critical strategy. North America currently leads the market, accounting for 39.9% of revenue share in 2025, with the U.S. being the largest contributor. The region's dominance is attributed to its robust research and development infrastructure, favorable reimbursement policies, and a high concentration of healthcare facilities equipped to adopt advanced technologies. Meanwhile, the Asia Pacific region is expected to experience the fastest growth, indicating a shift in market dynamics as emerging economies ramp up investments in healthcare technologies. The market is segmented into various product categories, with automated cytology screening systems holding a 33.7% revenue share in 2025. These systems leverage AI to automate the analysis of digitized slides, enhancing the speed and accuracy of abnormal cell detection. The gynecological cytology screening application is particularly significant, representing 75.6% of the market due to the ongoing emphasis on cervical cancer screening initiatives. Hospitals are the primary end-users, comprising 40.6% of the market, reflecting their critical role in implementing these technologies. The rising volume of cervical cancer screenings and preventive healthcare initiatives is intensifying the workload for pathology laboratories, which are often constrained by a lack of qualified specialists. This gap is driving investments in AI-assisted cytology solutions that can boost productivity and maintain diagnostic quality. For example, Hologic's Genius Digital Diagnostics System, which received FDA clearance, exemplifies how AI can enhance diagnostic workflows by automating slide evaluation and prioritizing high-risk cases for expert review. Despite the promising outlook, the market faces challenges, particularly the high implementation costs associated with transitioning to AI-enabled systems. Healthcare providers must invest in advanced imaging technologies, data storage solutions, and workforce training, which can be particularly burdensome for smaller institutions. This financial barrier limits the widespread adoption of AI technologies, especially in resource-constrained environments. The competitive landscape is characterized by ongoing innovation and strategic collaborations. Companies are focusing on expanding their product offerings to create integrated diagnostic solutions that address both workforce shortages and operational inefficiencies. The recent partnership between Synergy Laboratories and Hologic to implement AI-driven cervical cytology screening is a case in point, highlighting the growing commercial viability of these technologies. As the market evolves, the integration of AI into routine cytology practices is expected to accelerate. The demand for digital pathology solutions that facilitate remote consultations and centralized diagnostic services is increasing. This trend is likely to enhance the accessibility of advanced diagnostic technologies, particularly as cloud-based platforms become more prevalent. Looking ahead, the sustained emphasis on early cancer detection and the expansion of cervical cancer screening programs will create substantial opportunities for AI in cytology screening. Healthcare providers are increasingly prioritizing intelligent diagnostic solutions that can optimize testing capacity and improve the quality of diagnostic services. As regulatory approvals continue to support innovation, the market is set for robust growth, with AI-enabled cytology screening devices playing a pivotal role in transforming diagnostic workflows across global healthcare systems. The focus on developing scalable, integrated solutions will be critical for companies aiming to capitalize on this expanding market. Entities mentioned. Synergy Laboratories Aiforia Technologies Blackstone Genius Digital Diagnostics System Genius Cervical AI Aptima HPV Assay Technologies artificial intelligence deep learning digital pathology whole-slide imaging automated cytology screening systems AI cytology analysis software Organizations Key concepts. AI in cytology screening market growth diagnostic accuracy workforce shortages digital pathology integration cervical cancer screening automated slide evaluation regulatory impact Definitions. * AI in Cytology Screening - The use of artificial intelligence technologies to enhance the efficiency and accuracy of cytology diagnostics. * Automated Cytology Screening Systems - Systems that utilize AI to automate the analysis of cytological samples, improving diagnostic workflows. * Digital Pathology - The management and interpretation of pathology information in a digital format, facilitating remote consultations and integrated workflows. * Whole-Slide Imaging - A technology that captures high-resolution images of entire microscope slides, enabling digital analysis and storage. * Cervical Cancer Screening - The process of testing for cervical cancer in women, often using Pap smears and HPV testing. Use cases. * | Enhancing cervical cancer screening accuracy * | Automating routine cytology diagnostics * | Improving laboratory efficiency * | Facilitating remote consultations * | Optimizing specialist productivity * | Supporting workflow in pathology laboratories Frequently asked questions. What is driving the growth of AI in cytology screening? The growth is primarily driven by a shortage of skilled cytologists, increasing cervical cancer screening volumes, and the need for improved diagnostic accuracy and laboratory efficiency. How does AI improve diagnostic accuracy in cytology? AI enhances diagnostic accuracy by automating the analysis of digitized slides, prioritizing high-risk cases, and reducing the burden of manual evaluations, allowing specialists to focus on complex cases. What are the challenges in adopting AI-enabled cytology solutions? Challenges include high implementation costs, the need for robust digital pathology infrastructure, and the requirement for ongoing investments in training and regulatory compliance. What role do regulatory bodies play in the AI cytology market? Regulatory bodies like the U.S. FDA ensure the safety, performance, and clinical validation of AI-enabled diagnostic systems, fostering innovation and market confidence. What future trends are expected in the AI in cytology screening market? Future trends include increased integration of AI with digital pathology, expansion of cervical cancer screening programs, and advancements in cloud-based AI technologies to enhance diagnostic workflows.

جريدة البلاد

Aug 4th, 2026

Royal Medical Services launches advanced GEN 3 device for breast surgeries as first center in Kingdom of Bahrain

Royal Medical Services launches advanced GEN 3 device for breast surgeries as first center in Kingdom of Bahrain Tuesday, August 4, 2026 The Royal Medical Services has launched the advanced GEN 3 device from Hologic, which is the first of its kind in the Kingdom of Bahrain, in a step that enhances the accuracy and efficiency of breast surgeries by employing the latest advanced medical technologies. The device relies on Magseed technology to accurately locate non-palpable tumors before and during surgery, and Magtrace technology to help identify the sentinel lymph node, in addition to providing real-time guidance to the surgeon through audio signals and precise digital readings, which supports reaching the target area during the surgical procedure. On this occasion, His Excellency Major General Doctor Sheikh Fahd bin Khalifa bin Salman Al Khalifa, Commander of the Royal Medical Services, affirmed that the launch of the GEN 3 device reflects the Royal Medical Services' keenness to keep pace with global developments in breast surgery techniques, and to provide advanced medical solutions that contribute to supporting therapeutic teams and enhancing the level of services provided to patients. His Excellency pointed out that investing in modern technologies represents part of the Royal Medical Services' strategy aimed at elevating medical performance levels and providing healthcare according to the highest standards. For his part, Edward Rowland, CEO of the Bahrain Oncology Center, praised this step, explaining that the GEN 3 system represents a qualitative addition to breast surgeries, as it provides advanced capabilities that reduce reliance on traditional methods, such as the use of wires and radioactive materials, which contributes to enhancing patient comfort and improving the efficiency of surgical procedures. He added that the new system supports the surgical team in providing a more advanced treatment experience, in line with the latest global practices in this field. Dr. Nouf Al-Shaibani, Head of the Women's Health Center at the Royal Medical Services and Consultant of General Surgery and Reconstructive Surgery at the Bahrain Oncology Center, explained that the GEN 3 device represents an important development in breast surgeries, as it helps the surgical team deal with delicate cases with a higher level of accuracy and control, and improves planning for surgical procedures. She affirmed that this technology contributes to enhancing the patient experience and supporting the achievement of better treatment outcomes through the integration of medical expertise and advanced technology. The launch of the GEN 3 device comes as an extension of the Royal Medical Services' efforts to develop the healthcare system, and to enhance its position as a leading institution that combines medical expertise and innovation to provide health services according to the highest international standards.

HookPhish

Jun 28th, 2026

Ransomware Group Redact hits: hologic.

Ransomware Group Redact hits: hologic. HookPhish team Target organization Hologic hologic.com Healthcare Summary. In the latest cybersecurity news, Hologic - an organization based in US - has fallen victim to a ransomware attack conducted by the group Redact. This data breach, discovered on Jun 28, 2026, 08:38 UTC, underscores the increasing need for proactive cybersecurity defenses as Hookphish continue through 2026. Incident report. | Target Organization | Hologic | | Threat Group | Redact | | Summary | Sector: Medical Supplies | Revenue: $4B USD | | Date of Breach | Jun 28, 2026, 08:38 UTC | | Discovery Date | Jun 28, 2026, 08:38 UTC | | Region | US | | Target Domain | hologic.com | | Business Sector | Healthcare | How to reduce your ransomware risk. Most ransomware intrusions start with a stolen password or a phishing email. A few proactive steps sharply cut your exposure: * phishing simulations - close the gap attackers exploit. * awareness training - close the gap attackers exploit. Disclaimer. HookPhish does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.